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ABSTRACT 24 
 25 
There are limited data on the pharmacokinetic and safety profiles of dihydroartemisinin-26 
piperaquine (DHA-PQ) among human immunodeficiency virus infected (HIV+) individuals taking 27 
antiretroviral therapy (ART). In a two step (parallel-group) pharmacokinetic trial with intensive 28 
blood sampling, we compared area under the concentration-time curve (AUC0-28 days) and safety 29 
outcomes of piperaquine among malaria-uninfected HIV+ adults. In step 1,  half the adult dose 30 
of DHA-PQ was administered for three days as an intitial safety check  in four groups 31 
(n=6/group) of HIV+ adults (age≥18 years): (i) antiretroviral-naïve, (ii) on nevirapine-based ART, 32 
(iii) on efavirenz-based ART, and (iv) on ritonavir-boosted lopinavir-based ART. In step 2, a full 33 
adult treatment course of DHA-PQ was administered to a different cohort of participants in three 34 
groups: (i) antiretroviral naïve, (ii) on efavirenz-based ART and (iii) on nevirapine-based ART 35 
(n=10-15/group). Ritonavir-boosted lopinavir-based ART group was dropped in step 2 due to 36 
limited number of participants who were on this second line ART and were eligible for 37 
recruitment. Piperaquine’s AUC0-28 days in both steps was 43% lower among participants on 38 
efavirenz-based ART compared to ART naïve participants. There were no significant differences 39 
in AUC0-28 days between the other ART groups and the ART naïve group in each of the two steps. 40 
Furthermore, no differences in treatment-emergent clinical and laboratory adverse events were 41 
observed across the groups in steps 1 and 2. Although well tolerated at half and full standard 42 
adult treatment courses, efavirenz based antiretroviral regimen was associated with reduced 43 
piperaquine exposure which may compromise dihydroartemisinin-piperaquine’s effectiveness in 44 
programmatic settings. 45 
 46 
Key words: piperaquine, antiretroviral therapy, malaria  47 
 48 
 49 
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INTRODUCTION 50 
 51 
Human immunodeficiency virus (HIV) and Plasmodium falciparum (Pf) malaria infections are 52 
endemic in most areas in sub-Saharan Africa (SSA) and co-infections occur frequently. HIV 53 
infection increases susceptibility to malaria (1, 2), severity of Pf malaria (3–6) and reduces the 54 
efficacy of some antimalarial drugs in current use (7, 8). To combat these dual infections, the 55 
World Health Organisation (WHO) recommends initiation of antiretroviral therapy (ART) in HIV-56 
positive (HIV+) individuals and prompt use of artemisinin-based combination therapies (ACTs). 57 
Dihydroartemisinin-piperaquine (DHA-PQ), is one of the ACTs being used increasingly in SSA 58 
in malaria infected individuals (9) owing to its better safety profile and longer piperaquine half-59 
life of approximately 33 days (10, 11), which makes it an ideal option for treatment of 60 
uncomplicated Pf malaria (12, 13) and intermittent preventive treatment of malaria in pregnancy 61 
(14, 15). Additionally, dihydroartemisinin, which has a half-life of approximately 1 hour, is fast 62 
acting and 5-10 times more potent among the artemisinin derivatives (16). Because of the 63 
geographical overlap of malaria and HIV, DHA-PQ will likely be commonly co-administered with 64 
ART such efavirenz (EFV), nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r).  65 
 66 
It has been postulated that pharmacokinetic interactions between ACTs and non-nucleoside 67 
reverse transcriptase inhibitors (NNRTI)- or protease inhibitors (PIs)-containing ART are likely 68 
since these classes of drugs affect the activity of cytochrome-P (CYP) 450 liver enzymes. 69 
NNRTIs such as NVP and EFV usually induce various CYP450 isoforms but they are also 70 
substrates for CYP450 enzymes as are ACTs. Conversely, HIV PIs, particularly ritonavir, are 71 
potent inhibitors of CYP3A enzymes (17), which form part of the CYP450 enzyme entity. 72 
Administration of ACTs in HIV+ individuals on ART may therefore reduce or increase plasma 73 
concentrations of any of the drug components of ACTs. Dihydroartemisinin may have limited 74 
pharmacokinetic interactions with ART since it is metabolised through glucuronidation by uridine 75 
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diphosphate glucuronosyltransferase (18). However, piperaquine, as a xenobiotic, is 76 
metabolised by CYP P450 (CYP3A4 and CYP2C8) for excretion (19). Any induction or inhibition 77 
of these enzymes by ART may affect clearance of piperaquine and, therefore, its efficacy and 78 
safety.     79 
 80 
In a two-step (parallel), intensive pharmacokinetic sampling trial, we compared the safety of 81 
DHA-PQ and secondary pharmacokinetic parameters (AUC0-28 days, Cmax, tmax, t1/2) of piperaquine 82 
between HIV+ adults taking various ART (efavirenz-, nevirapine-, ritonavir-boosted lopinavir-83 
based regimens) and HIV+ adults not on any ART. 84 
 85 
MATERIALS AND METHODS 86 
 87 
Study Design and population 88 
We conducted an open-label, sequential group, PK trial, from August 2010 to March 2013, at 89 
Queen Elizabeth Central Hospital, Malawi. The study was implemented in the following two 90 
steps: 91 
 92 
 In step 1 [PACTR2010030001871293], we administered half adult doses of the DHA-PQ 93 
(Euratesim®, Sigma Tau) to the followin groups of malaria-negative research participants 94 
(n=6/group):  95 
1) An antiretroviral naive HIV+ (control) group  96 
2) HIV+ individuals on NVP-based ART  97 
3) HIV+ individuals on EFV-based ART 98 
4) HIV+ individuals on LPV/r-based ART   99 
DHA-PQ was administered orally at 0, 24 and 48 hours (once daily for 3 days). One tablet (each 100 
containing DHA/PQ 40mg/320mg) was administered orally for study participants weighing 101 
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<60kgs and 1.5 tablets to participants weighing >= 60kg. Food intake, including fat containing 102 
food, was not restricted. This step served as a safety evaluation step for the drug interaction 103 
studies, checking for unexpected clinical toxicities or interactions.  104 
 105 
In step 2 [PACTR2010030001971409], after review and consideration of step 1 data by an 106 
independent Data Safety Monitoring Board (DSMB), a full standard dose DHA-PQ (3 tablets to 107 
study participants weighing < 60kg and 4 tablets to those weighing >= 60kg) was administered 108 
to 40 adults in the following groups of malaria-negative research participants (different from 109 
those enrolled in step 1):  110 
1) An antiretroviral naive HIV+ (control) group  111 
2) HIV+ individuals on NVP-based ART  112 
3) HIV+ individuals on EFV-based ART 113 
DHA-PQ was administered at 0, 24 and 48 hours (once daily for 3 days). The group of HIV+ 114 
individuals on LPV/r-based ART was dropped owing to limited number of participants available 115 
for recruitment into the study. Unlike in step 1, DHA-PQ was administered with water only in 116 
step 2; no food was given to study participants taking DHA-PQ within a period of 3 hours before 117 
and 3 hours after administering the drug; based on a new recommendation from the drug 118 
manufacturer, Sigma Tau. In the ART arms, the first dose of DHA-PQ was timed to coincide 119 
with the next scheduled dose of the ART. 120 
 121 
The study population for step 1 and step 2 were HIV+ male and non-pregnant female 122 
participants aged ≥18 years residing in Blantyre, Malawi or neighbouring districts of Thyolo and 123 
Chiradzulu. Individuals on ART were eligible to participate if they had been on NVP, EFV or 124 
LPV/r-based ART for ≥ 6 months and had CD4 cell count ≥ 250 cells/mm3. At the beginning of 125 
the study, HIV+ antiretroviral naive individuals were eligible for ART if they had a CD4 cell count 126 
≥ 250/mm3 but this cut-off point was increased to ≥350/mm3 when the WHO criteria for ART 127 
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initiation changed in July 2011. Other inclusion criteria were body weight ≥40kg and willingness 128 
to be admitted in the hospital for 3 days, to remain within the study sites and to be contacted at 129 
home or by phone during the course of the study.  130 
 131 
We excluded participants who had body mass index ≤18.5kg/m2, haemoglobin concentration 132 
<8.5 g/dL, reported use of any antimalarial drugs within the preceding 4 weeks, reported 133 
hypersensitivity to any of the ACTs, were taking other drugs which are known inhibitors or 134 
inducers of P450 enzymes or P-glycoprotein (except cotrimoxazole prophylaxis), had a history 135 
of regular intake of alcohol (>twice/week), tobacco (>3 times/week) or any use of illicit drugs,  136 
had a history or evidence of pre-existing liver, kidney or heart disease, including conductive 137 
abnormalities on electrocardiographs (QTc interval>450ms in men and >470ms in females), had 138 
clinical and/or laboratory evidence of Pf malaria, hepatitis B, pneumonia, tuberculosis, 139 
bacteraemia or laboratory evidence of potentially life threatening white blood cell disorders such 140 
as absolute neutrophil count <0.500*109/L, absolute lymphocyte count <0.35*109/L or absolute 141 
platelet count <25*109/L. Participants with a performance (Karnofsky) score of <80% and who 142 
were participating in any other clinical trial were also not included.  143 
 144 
In step 1, the sample size was 6 in each of the DHA-PQ/ART and control (ART-naive) groups. 145 
This sample size was based on standard practice in early PK studies of antimalarial drugs which 146 
aim to safeguard the safety of study subjects and minimize the number of subjects who may be 147 
potentially exposed to harmful drug levels. In step 2, a sample size of 15 per group in the DHA-148 
PQ/ART groups and 10 in the ART-naive group was required. This was calculated to detect a 149 
two-fold increase in PQ AUC in any of the DHA-PQ/ART groups compared with the ART-naive 150 
group, assuming a mean (standard deviation) PQ AUC of 19.4 (15.0) mcg/hr/mL (17) in the 151 
ART-naive group, with power set at 90% and level of significance at 5%. 152 
 153 
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Ethics and data collection procedures 154 
The design and timing of trial procedures was approved by the College of Medicine Research 155 
Ethics Committee (COMREC), in Blantyre, Malawi. The study conformed to the principles of the 156 
International Conference on Harmonization on Good Clinical Practice. Research nurses and 157 
clinicians sought written informed consent from individuals to perform screening procedures 158 
including physical medical and anthropometric assessment, electrocardiographs (ECGs) and 159 
blood tests to detect blood-borne infections, haematological, renal or hepatic abnormalities. 160 
Results from screening procedures were available within 7 days of screening. Based on these 161 
results, potential study participants were informed of their eligibility to participate in the study. 162 
Thereafter, research nurses or clinicians sought written informed consent from eligible subjects 163 
to participate in the study.  164 
 165 
Pre-DHA-PQ dosing procedures 166 
Consenting study participants were re-assessed by research nurses or clinicians to determine 167 
whether they still met all eligibility criteria, through repeat history taking and physical 168 
examination. Eligible participants were admitted in hospital and an indwelling cannula was 169 
inserted into a vein before their scheduled dose of ART and the first dose of the ACT. 170 
Approximately 1 hour before the scheduled time of ART and ACT dosing, blood samples were 171 
collected for haematological, renal and liver function tests and also random glucose test. 172 
 173 
Blood sample collection and processing 174 
While the participant was hospitalized, blood samples for pharmacokinetic (PK) assays were 175 
collected in heparin vacutainer tubes, pre-treatment and at the following post-treatment times:  176 
0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60 and 72 hours. After discharge, the blood 177 
samples were taken at the following times; 4, 5, 6, 7, 14, 21 and 28 days. Immediately after 178 
collection, the blood samples were spun in a refrigerated centrifuge and the separated plasma 179 
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samples were temporarily frozen in liquid nitrogen before transferred to a -80˚C freezer until 180 
HPLC analyses.  181 
 182 
Safety Assessments 183 
After the first dose of DHA-PQ, blood samples to detect haematological, renal and liver function 184 
abnormalities were collected at the following times; 12, 48 and 72 hrs and at days 7, 14, 21 and 185 
28. In addition, 12-lead ECGs were performed pre-dosing, 5 hours after the first dose and 5 186 
hours after the last dose to assess Fridericia’s-corrected QTc interval (20). The study focussed 187 
on treatment-emergent adverse events (TEAEs), defined as clinical or subclinical abnormalities 188 
which were absent before dosing with DHA-PQ but emerged post dosing or those which were 189 
present before dosing with DHA-PQ but worsened post-dosing. Severity of AEs was graded 190 
using the DAIDS criteria (21) while seriousness was defined according to the standard 191 
definition.  192 
 193 
Pharmacokinetic assays  194 
Plasma samples were analysed for PQ levels at Malawi-Liverpool Welcome Trust Clinical 195 
Research Programme in Blantyre, Malawi, using a validated HPLC-UV assay adopted and 196 
transferred to Malawi from the Liverpool School of Tropical Medicine. The PK laboratory in 197 
Blantyre participated in WWARN’s External Quality Assurance programme (22). Briefly, PQ and 198 
the internal standard (Chloroquine) were recovered from plasma using diethyl/tert-butyl ether. 199 
The supernatant was evaporated to dryness in a vacuum concentrator at 25 0C. The residue was 200 
re-dissolved in 200 µl of the reconstitution solvent acetonitrile: phosphate buffer (5:95, pH 2.5) 201 
and 75 µL was injected into the chromatograph (Agilent 1100). Quantitation of the drugs was 202 
achieved by reverse phase HPLC. The optimum detection wavelength for each drug was 345 nm. 203 
The lower limit of quantitation (LLQ) of the piperaquine HPLC-UV assay was 0.025 µg/mL with 204 
CV<10%. Reconstituted plasma sample extracts were run in batches comprising all samples 205 
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collected from each of any two study participants. Each batch run included a blank plasma 206 
extract, two sets of 8-concentration-level calibration standards, and quality controls (QC) at 207 
three concentration levels: low, medium and high (0.025, 1.5 and 3.0 µg/mL for PQ. For batch 208 
assay to pass the measured concentrations of at least 67% of the QC samples had to be within 209 
+/-20% of their nominal value and at least one QC had to be acceptable at the LLQ. The mean 210 
inter-assay precision for low, medium and high QCs was 7%, 12% and 10% respectively. In 211 
addition, 75% of each calibration curve's concentrations had to lie within +/-20% and +/-15% of 212 
the nominal concentration at the LLQ or all other concentrations.  213 
 214 
Pharmacokinetic and safety data analyses  215 
Plasma concentrations of piperaquine were analysed using non-compartmental 216 
pharmacokinetic analysis (NCA), employing the trapezoidal rule with cubic splines. Observed 217 
piperaquine concentrations below the lower limit of quantification (<LLOQ) were treated as 218 
missing data except for the pre-dose concentration which was imputed to 0 if below LLOQ. For 219 
each study participant, the following PK parameters were computed: AUC0-28 days, maximum 220 
concentration [Cmax], time to maximum concentration [tmax] and terminal elimination half-life [t1/2]). 221 
We used STATA 15.0 for the NCA and to compare log-transformed PK parameters. Geometric 222 
mean ratios with 90% confidence intervals have been presented. To test for significant 223 
differences in PK parameters between each ACT/ART group and the ART-naïve group, 224 
parametric evaluation of the log-transformed PK parameters was done using analysis of 225 
variance (ANOVA) (α=0.1). Fisher’s exact test was used to compare proportions of participants 226 
across the study groups with day 7 concentrations that were above a value known to predict 227 
treatment response by day 28, and of safety parameters across the different ACT/ART groups 228 
in comparison to the ART naïve group. Data summaries and graphics were all performed in 229 
STATA 15.0.  230 
 231 
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RESULTS 232 
 233 
Characteristics of study participants  234 
In step 1, 24 participants (6 in each group) were enrolled and successfully followed up for 28 235 
days, including 5 who replaced those withdrawn due to protocol violations. In step 2, 40 236 
participants were enrolled (10 in ART naïve and 15 in each of EFV and NVP groups) and 237 
completed 28 days of follow-up, including 2 who replaced those withdrawn due to protocol 238 
violations. In accordance with the protocol, withdrawn individuals were not included in the PK 239 
analyses. As shown in Table 1, participants who completed follow-up in steps 1 and 2 generally 240 
had similar baseline characteristics. In step 1, those on ritonavir-boosted lopinavir had longer 241 
median duration of ART intake than those on EFV and NVP groups. In addition, baseline 242 
alanine aminotransferase was higher in those on EFV based ART. 243 
 244 
Pharmacokinetic interactions between piperaquine and ART in step 1 245 
Participants in the EFV-ART group had 43% lower AUC0-28 days of piperaquine compared to the 246 
ART naïve group (geometric mean ratio [90% CI]: 0.57 [0.38-0.83]; p=0.029). There were no 247 
significant differences in AUC0-28 days among participants in the other ART groups in comparison 248 
to the ART naïve group. Piperaquine’s Cmax was higher in the NVP-ART group than in the ART 249 
naïve group (geometric mean ratio [90% CI]: 1.82 [1.13-2.94]; p=0.061), but no significant 250 
differences in Cmax were observed between the rest of the ART groups and the ART naïve 251 
group. There were no significant differences in the t1/2 of piperaquine in all four study groups (as 252 
shown in Table 2a). However, the median tmax was higher in the LPV/r-ART group than in the 253 
ART naïve group (p=0.049). Figure 1 shows a concentration-time profile between ART groups 254 
and the ART naïve group. Compared to the ARV-naïve group, there was a lower piperaquine 255 
concentration-time profile in the EFV-ART group.  256 
 257 
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Safety assessment in step 1 258 
DHA-PQ was well tolerated in all study groups. However, one participant in the ART-naive 259 
group had a 3-day history of headache, heart palpitations, nausea with no vomiting and good 260 
appetite following intake of DHA-PQ. These resolved by day 7 of follow up. One participant in 261 
the NVP-ART group developed left sided hemiplegia which was not thought to be associated 262 
with co-administration with DHA-PQ. There were no clinically-significant treatment-emergent 263 
haematological or hepatic abnormalities across the study groups.   264 
 265 
Pharmacokinetic interactions between piperaquine and ART in step 2 266 
In step 2, piperaquine’s AUC0-28 days was 43% lower in the EFV-ART group compared to the 267 
ART-naïve group (geometric mean ratio [95% CI]: 0.57 [0.44-0.74]; p=0.002). There was no 268 
significant difference in piperaquine’s AUC0-28 days between the NVP/ART and ART-naïve groups. 269 
Furthermore, participants in the EFV-ART group had 43% lower Cmax of piperaquine compared 270 
to the ART naïve group (geometric mean ratio [95% CI]: 0.57 [0.36-0.90]; p=0.065), and 271 
piperaquine’s t1/2 was 64% lower in the EFV-ART group than in the ART naïve group (geometric 272 
mean ratio [95% CI]:0.36 [0.15-0.87]; p=0.072). However, there were no significant differences 273 
in the Cmax and t1/2 of piperaquine between the NVP-ART and the ART naïve groups as shown in 274 
Table 2b. Similarly, no significant differences in the median tmax between the two ART-groups 275 
and the ART naïve group were observed. Figure 2 illustrates the piperaquine concentration 276 
versus time plot in the NVP, EFV and ART-naive groups in step 2. The EFV-ART group had a 277 
lower concentration-time profile of piperaquine compared to the ART naïve group and there was 278 
a tendency towards higher piperaquine concentration in the NVP-ART group compared to the 279 
ART naïve group.  280 
 281 
 282 
 283 
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Piperaquine day 7 concentrations 284 
Of the 40 participants in step 2, 22 had piperaquine plasma concentration above the lower limit 285 
of quantification (>25ng/mL) at day 7 post-treatment. There was no evidence of a significant 286 
difference in day 7 piperaquine concentration across the ART groups (Table 2b). Of the 22 287 
participants with day 7 piperaquine concentration above >25ng/mL (ART naïve=2, EFV-ART=10 288 
and NVP-ART=10), the proportion achieving piperaquine concentrations >30ng/mL was 90% 289 
(n=10) in ART-naïve group, 100% (n=2) in EFV-ART and 90% (n=10) in the NVP-ART group. 290 
There was no evidence of a difference in these proportions between each of the EFV and NVP-291 
ART groups compared to the ART naïve group (for both comparisons; EFV/NVP-ART vs ART 292 
naïve; p= 1.000). 293 
 294 
Safety assessment in step 2  295 
DHA-PQ was generally well tolerated in all study groups in step 2. However, one participant in 296 
the ART-naïve group reported nausea following intake of DHA-PQ but this resolved within a 297 
day. The proportions of study participants who had any grade of treatment emergent 298 
transaminitis (elevated ALT and AST levels) after DHA-PQ administration were similar in the 299 
ART-naïve and EFV-ART, 50% (5/10) vs 40% (6/15) respectively; p=0.697, and between the 300 
ART-naïve and NVP-ART 53% (8/15) groups (p=1.000). None of the elevated AST or ALT 301 
levels reached severity levels of grade 3 or 4 or were persistent beyond day 28 of follow up. The 302 
proportions of participants who had any grade of treatment-emergent neutropenia after DHA-PQ 303 
administration were similar between the ART-naïve, 30% (3/10) and the EFV-ART-group, 33% 304 
(5/15) p=1.000, between the ART-naïve group and the NVP-ART, 20% (3/15) groups (p=0.653). 305 
There were no cases reaching grade 3 or 4 neutropenia in any of the groups. Additionally, the 306 
proportion of participants who had QTc prolongation after DHA-PQ administration (470ms at 307 
day 3 of follow up) were 0.0% (0/10), 13.3% (2/15) and 13.3% (2/15) in the ART naïve, EFV-308 
ART and NVP-ART groups respectively, with no evidence of significant difference between the 309 
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NVP/EFV-ART groups and the ART-naïve group. All cases of QTc prolongation resolved 310 
spontaneously by day 21 of follow up.   311 
 312 
Dose proportionality between ART naïve participants in steps 1 and 2 313 
Assuming linear disposition of piperaquine, increasing the dose in step 2 should result in 314 
increased AUC0-28 days in this step compared to step 1. As part of an exploratory analysis, not 315 
determined a priori, we assessed dose proportionality between the ART naïve groups in steps 1 316 
and 2 using a linear quadratic regression approach by regressing dose normalised AUC0-28 days 317 
(AUC0-28 days/ Dose) with total dose received by each participant (23). The fitted linear regression 318 
equation was:  319 
AUC0-28 days/Dose= alpha + beta1*Dose + beta2*Dose^2  (a)  320 
The null hypothesis was that beta2 and alpha are equal to zero. Dose proportionality was 321 
declared if alpha and beta2 were not significantly different from zero. The above equation could 322 
be further simplified to the equation below when beta2 is not significantly different from zero: 323 
 AUC0-28 days/Dose= alpha + beta*Dose   (b) 324 
Both equations showed no evidence against the null hypothesis as illustrated below in the result 325 
of the equation (a), which was derived from ART naïve participants in steps 1 and 2, showing 326 
that beta2 and alpha were not very significantly different from zero: 327 
AUC0-28 days/Dose= 0.116 - 0.00011*Dose + 3.37e-08*Dose^2  328 
 329 
DISCUSSION 330 
 331 
The aim of this study was to compare secondary pharmacokinetic parameters of piperaquine 332 
and safety of dihydroartemisinin-piperaquine between HIV infected adults taking various 333 
antiretroviral therapy (efavirenz, nevirapine, ritonavir-boosted lopinavir based regimens) and 334 
HIV infected adults not on any antiretroviral therapy. We found that co-administration of 335 
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piperaquine and efavirenz based ART regimen significantly lowered piperaquine’s exposure 336 
(AUC0-28days) at half and full standard adult courses, and reduced piperaquine’s half-life and 337 
achieved maximum concentration at full standard adult course than when administered alone 338 
among non-malaria-HIV infected adults. Additionally, the day 7 piperaquine concentration was 339 
not significantly different between the ART-groups following intake of a full standard adult 340 
course.  Furthermore, DHA-PQ was well tolerated at both half and full adult courses across all 341 
ART groups with no evidence of significant differences in treatment emergent clinical and 342 
laboratory adverse events across all ART-groups.  343 
 344 
The finding of a significantly lower piperaquine concentration in the EFV group in both steps is 345 
consistent with known metabolism of EFV, which is a potent inducer of CYP3A4 (17) and is one 346 
of the major CYP450 isoforms responsible for metabolic clearance of piperaquine (24). There is 347 
paucity of published evidence on the interaction between piperaquine and ART among non-348 
pregnant individuals. However, our findings are consistent with previous findings among 349 
pregnant women receiving DHA-PQ for intermittent preventive treatment of malaria in Uganda, 350 
where piperaquine exposure was shown to be 38% lower among pregnant women receiving 351 
EFV based ART compared to HIV uninfected pregnant women (25). Thus, in the present study, 352 
EFV induction of CYP3A4 in the EFV-treated group might have led to enhanced clearance and 353 
shorter half-life of piperaquine seen in step 2.  354 
 355 
Unexpectedly, we found non-significantly higher concentration of piperaquine in the NVP based 356 
ART group in steps 1 and 2 than in the ART naïve group. While there is some evidence that 357 
NVP induces CYP3A4 (26, 27), other studies have suggested that it may act as an inhibitor of 358 
other drugs metabolised by the CYP3A4 as shown with increased Cmax and AUC of darunavir 359 
(28) and maraviroc (29), when co-administered with NVP. The non-significantly increased AUC0-360 
28 days and Cmax of piperaquine in our study could suggest increased bioavailability or reduced 361 
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metabolism. As this study was not designed to elucidate the mechanism of interaction between 362 
piperaquine and nevirapine, studies in future should aim to explore and define these 363 
mechanisms which could include competitive inhibition of metabolic enzymes (30) or variations 364 
in availability of proteins to transport drugs (31).  365 
 366 
Evidence on the interaction between piperaquine and LPV/r-based ART is sparse. In step 1, we 367 
found an expected but non-significant tendency towards higher piperaquine exposure (AUC0-28 368 
days) in the LPV/r ART group compared to the ART naïve group and were unable to further 369 
evaluate this finding with a larger sample size in step 2 due to a limited number of study 370 
participants on this second line ART regimen during the study period. Since LPV/r is 371 
increasingly being used in malaria-HIV endemic settings as second line antiretroviral therapy, its 372 
impact on piperaquine’s PK profile needs to be further studied. 373 
 374 
Previous studies found that lower day 7 plasma piperaquine concentrations are associated with 375 
recurrent malaria (32, 33).  The lack of significant evidence of a difference in day 7 piperaquine 376 
concentrations between the EFV or NVP-ART groups and ART-naïve group could be due to the 377 
small number of participants that had day 7 piperaquine concentrations that were above the 378 
lower limit of quantification of our assay, which may not have been able to detect low 379 
piperaquine concentrations.  As efavirenz has been shown to also lower day 7 piperaquine 380 
concentrations in pregnancy (25), future studies should further explore this in HIV infected, non-381 
pregnant adults.  382 
 383 
We found no major differences in the incidence of neutropenia and transaminitis and QTc 384 
prolongation across the various ART groups, which is reassuring. However, these results need 385 
to be interpreted with caution, since this study was not powered to detect differences in safety 386 
endpoints.  387 
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Concomitant intake of piperaquine with food has previously been shown to increase 388 
bioavailability of piperaquine (34). Lack of food restriction in step 1, including intake of fat 389 
containing food, may have resulted in increased absorption of piperaquine in this step, with 390 
subsequent higher AUC0-28days in step 1 than in step 2. Although assessing dose proportionality 391 
was not the primary aim of this study, dose normalisation of the AUC0-28days (adjusting for the 392 
effect of the total administered dose) showed that there was evidence of dose proportionality 393 
between the two steps. The inability to detect significant differences in PK parameters, including 394 
dose proportionality between steps1 and 2, may be due to the use of the parallel-group design 395 
which is more prone to effects of inter-individual anthropometric and genetic variations than a 396 
cross-over design. Thus, other covariates such as genetic polymorphisms in CYP450 iso-397 
enzymes may have contributed to very wide interquartile ranges of PQ PK parameters observed 398 
within each study group and between the two steps. However, our study sample size is unlikely 399 
to have missed large (>2-fold), clinically important differences in AUC across the study arms.  400 
Nevertheless, future studies need to assess the effect of genetic polymorphisms in CYP450 iso-401 
enzymes on the pharmacokinetics of piperaquine and quantify any changes in plasma ART 402 
levels when co-administered with antimalarial drugs.  403 
 404 
In our study, we did not assess the impact of ART on the PK profile of the faster acting and 405 
potent partner drug of piperaquine, dihydroartemisinin. In future, studies should aim to examine 406 
any potential impact of ART on the PK profile of dihydroartemisinin and evaluate its association 407 
with parasite clearance rates among malaria-HIV co-infected individuals. 408 
 409 
In conclusion, this study found that although generally well tolerated, co-administration of 410 
piperaquine and efavirenz based ART regimen significantly lowered piperaquine’s exposure 411 
among non-malaria HIV infected adults compared to an ART -naïve subgroup.  There were no 412 
major variations in piperaquine’s exposure among the ART naïve and participants on nevirapine 413 
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and ritonavir-boosted lopinavir based ART. The pharmacodynamic implications of these findings 414 
need to be evaluated in programmatic settings especially in malaria-infected individuals.  415 
 416 
 417 
 418 
 419 
 420 
 421 
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 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
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LEGENDS 570 
 571 
Figure 1. Piperaquine concentration-time profile (semi-logarithmic scale) following 572 
administration of half of the standard dihydroartemisinin-piperaquine adult dose in step 573 
1, n=23 (one participant excluded. ART-naïve, n=6; efavirenz (EFV), n=6; ritonavir-574 
boosted lopinavir lopinavir-boosted (LPV/r), n=6; nevirapine (NVP), n=5. Below lower 575 
limit of quantification concentrations are excluded resulting in plotted observation time 576 
up to 336 hours in the efavirenz group and 672 hours in the rest of the study groups. 577 
Data are represented as mean (95% confidence interval) 578 
 579 
Figure 2. Piperaquine concentration-time profile (semi-logarithmic scale) following 580 
administration of full standard adult dose of dihydroartemisinin-piperaquine in step 2, 581 
n=40. (ART naïve, n=10; efavirenz (EFV), n=15; nevirapine (NVP), n=15). Below lower 582 
limit of quantification points are excluded resulting in plotted observation time up to 336 583 
hours. Data are represented as mean (95% confidence interval) 584 
 585 
 586 
 587 
 588
 589 
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Table 1: Baseline Characteristics for study participants in Step 1 and Step 2 
 
 
 
 
 
Characteristic 
Step 1  Step 2  
DHA-PPQ+NVP 
Containing ART 
N=5 
DHA-PPQ +EFV 
Containing ART 
N=6 
DHA-PPQ +LPV/r 
Containing ART 
N=6 
DHA-PPQ 
without ART 
N=6 
P-value DHA-PPQ+NVP 
Containing ART 
N=15 
DHA-PPQ +EFV 
Containing ART 
N=15 
DHA-PPQ without 
ART 
N=10 
P-value 
Gender (n, % female) 3 (50.0) 2 (33.3) 2 (33.3) 4 (66.7) 0.811 13 (86.7) 13 (86.7) 5 (50.0) 0.071 
Median age (range, years) 39 (34–62) 43 (36–56) 41 (20–63) 29 (23–46) 0.360 36 (28–44) 36 (24–60) 40 (33–62) 0.060 
Mean haemoglobin (SD, g/dL) 13.9 (1.3) 12.7 (1.6) 13.1 (1.6) 12.9 (1.0) 0.633 13.3 (2.1) 13.4 (2.2) 13.9 (2.9) 0.830 
Median Body Mass Index (range in 
kg/m
2
) 
24.3 (22.0–25.5) 20.4 (18.7–23.1) 19.8 (17.5–25.7) 23.9 (19.9–26.4) 0.071 23.1 (18.0–28.8) 20.9 (16.0–19.0) 21.3 (18.4–27.4) 0.602 
Median (range) duration of ART 
intake at the time of screening (in 
months) 
26.3 (7.0–55.7) 24.5 (15.2–49.9) 65.7 (52.2–86.9) NA 0.020 47.7 (10.2–80.4) 39.8 (7.1–120.1) NA 0.371 
On Cotrimoxazole prophylaxis, n 
(%) 
6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 1.000 13 (86.7) 13 (86.7) 7 (70.0) 0.511 
ALT (IU/L) 26 (12–39) 35 (20–44) 20 (15–23) 18 (11–19) 0.024 23 (15–39) 22 (11–38) 21 (17–28) 0.750 
% with AST >ULN n (%) 2 (33.3) 4 (66.7) 0 (0.0) 0 (0.0) 0.092 5 (33.3) 3 (20.0) 3 (30.0) 0.743 
 o
n
 M
ay 21, 2018 by UNIV O
F CAPE TO
W
N LIBRARIES ELECTR JNLS O
NLY
http://aac.asm
.org/
D
ow
nloaded from
 
AST (IU/L) 27 (19–58) 39 (24–46) 29.5 (21–35) 23 (19–27) 0.081 27 (17–52) 29 (21–53) 28 (20–34) 0.524 
% with ALT >ULN n (%) 2 (33.3) 3 (50.0) 0 (0.0) 0 (0.0) 0.284 3 (20.0) 3 (20.0) 2 (20.0) 1.000 
Creatinine (umol/L) 67 (42–139) 57 (38–67) 73 (44–90) 58 (51–69) 0.332 60 (41–83) 55 (32–69) 59 (47–68) 0.871 
% with Creatinine >ULN n (%) 2 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0.221 0 (0.0) 0 (0.0) 0 (0.0) 1.000 
Any anemia, n (%) 
 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 2 (22.0) 0 (0.0) 0 (0.0) 0.330 
Any leucopenia, n (%) 
 
0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1.000 5 (33.3) 1 (6.7) 3 (30.0) 0.232 
Any neutropenia, n (%) 
 
2 (33.3) 2 (33.3) 4 (66.7) 1 (16.7) 0.460 3 (20.0) 5 (33.3) 3 (30.0) 0.741 
Any thrombocytopenia, n (%) 
 
0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1.000 4 (26.7) 1 (6.7) 1 (10.0) 0.410 
Median CD4 cell count (range, 
cells/UL) 
441 (254–832) 386 (273–757) 422 (375–691) 411 (324–734) 0.670 476 (298–685) 389 (274–1222) 429 (393–888) 0.311 
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Table 2a: Piperaquine pharmacokinetic parameters for participants in step 1     
  Study groups   Geometric Mean Ratio [90% CI] (p-value) 
  ART naïve                             
n=6 
NVP                                
n=5
§
 
LPV/r                             
 n=6 
EFV                                 
n=6 
NVP/ART naïve LPV/r/ART naïve EFV/ART naïve 
AUC0-28 days, hr.ng/mL 33385 [26131-42652] 43632 [31383-60662] 38300 [27256-53802] 18914 [14144-25291] 1.31 [0.86-1.99] (0.290) 1.15 [0.75-1.76] (0.589) 0.57 [0.38-0.83] (0.029) 
Cmax (ng/mL) 350 [252-485] 637 [453-897] 327 [263-406]  253 [156-412] 1.82 [1.13-2.94] (0.061) 0.94 [0.63-1.39] (0.775) 0.72 [0.40-1.32] (0.371) 
tmax (hr) 3 [2-60] 4 [3-5] 60 [60-60] 3 [2-60] 0.573
a
 0.049
a
 1.000
a
 
t1/2 (hr)* 332 [174-631] 319 [262-388] 455 [186-1114] 227 [120-432] 0.36 [0.49-1.89] (0.915) 1.37 [0.44-4.31] (0.636) 0.68 [0.36-1.30] (0.658) 
PK parameters are presented as geometric mean [90% confidence interval] except tmax which is presented as median [interquartile range].  
  
P-value is calculated using analysis of variance (ANOVA) in Stata ϭ5.Ϭ, α= 0.1 
     
ART=antiretroviral therapy; NVP=Nevirapine-based ART; EFV=Efavirenz-based ART; LPV/r=Ritonavir boosted lopinavir based ART  
 
Cmax=maximal concentration, tmax=time to reach maximal concentration, t1/2=drug elimination half-life 
AUC0-28 days =area under the concentration-time curve from 0 to 28 days      
§: One participant did not complete follow up and was excluded from analysis     
a: p-value only, calculated using Wilcoxon rank sum test, α= Ϭ.Ϭ5      
* Half-life estimation excluded below lower limit of quantification values     
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Table 2b: Piperaquine pharmacokinetic parameters for participants in step 2   
  Study groups   Geometric Mean Ratio [90% CI] (p-value) 
  ART naïve                                          
n=10 
NVP                                                 
n=15 
EFV                                           
n=15 
NVP/ART naïve EFV/ART naïve 
AUC0-28 days, 
hr.ng/mL 
27573 [23208-32759] 36747 [28419-47516] 15792 [13094-19048] 1.33 [0.98-1.82] (0.179) 0.57 [0.44-0.74] (0.002) 
Cmax (ng/mL) 430 [315-587] 557 [424-731] 245 [175-343] 1.30 [0.85-1.96] (0.314)  0.57 [0.36-0.90] (0.065) 
tmax (hr) 60 [60-60] 60 [36-60] 60 [24-60] 0.841
a
 0.441
a
 
t1/2 (hr)* 136 [72-255] 76 [36-160] 49 [27-90] 0.56 [0.21-1.51] (0.356) 0.36 [0.15-0.87] (0.072) 
Cd7 (ng/mL)
 #
 53 [39-71] 62 [46-84] 39 [32-48] 1.17 [0.76-1.83] (0.519) 0.74 [0.51-1.07] (0.469) 
PK parameters are presented as geometric mean (90% confidence interval) with exception of tmax which is given as median [interquartile range].  
P-value is calculated using analysis of variance ;ANOVAͿ in Stata ϭ5.Ϭ, α= 0.1 
 
  
ART=antiretroviral therapy; NVP=Nevirapine-based ART; EFV=Efavirenz-based ART.   
 Cmax=maximal concentration, tmax=time to reach maximal concentration, t1/2=drug elimination half-life.  
AUC0-28 days=area under the concentration-time curve from day 0 to 28, Cd7= day 7 piperaquine concentration   
* Half-life estimation excluded below lower limit of quantification values for each participant   
a: p-value only, calculated using Wilcoxon rank sum test, α= Ϭ.Ϭ5    
#: Day 7 piperaquine n=22, below lower limit of quantification values excluded resulting in number of observations as follows ART naïve=2, NVP=10, EFV=10 
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